AT9283 exhibits antiproliferative effect on tyrosine kinase inhibitor-sensitive and -resistant chronic myeloid leukemia cells by inhibition of Aurora A and Aurora B

TOMOYA TAKEDA1, MASANOBU TSUBAKI1, SHUJI GENNO1, CHISATO NEMOTO1, YASUKA ONISHI1, YUUTA YAMAMOTO1, MOTOHIRO IMANO2, TAKAO SATOU3 and SHOZO NISHIDA1

1Division of Pharmacotherapy, Kindai University School of Pharmacy, Higashi-Osaka, Osaka 577-8502; Departments of 2Surgery and 3Pathology, Kindai University School of Medicine, Osakasayama, Osaka 589-0014, Japan

Received March 21, 2020; Accepted July 13, 2020

DOI: 10.3892/or.2020.7739

Abstract. Imatinib is the gold standard in the conventional treatment of chronic myeloid leukemia (CML). However, some patients become resistant to imatinib therapy. To overcome this resistance, second-generation (dasatinib, nilotinib, and bosutinib) and third-generation (ponatinib) tyrosine kinase inhibitors (TKIs) have been developed and have been shown to be effective against refractory CML. Although these TKIs provide many benefits for patients with CML, advanced patients show resistance even to these TKIs. Therefore, novel therapeutic strategies are urgently needed for the treatment of TKI-resistant CML patients. AT9283 is a multi-targeted kinase inhibitor with potent activity against Janus kinase (JAK), Aurora kinases, and Abl. In the present study, we showed that AT9283 significantly decreased the cell viability of both TKI-sensitive and TKI-resistant CML cells as determined by trypan blue exclusion assay. In addition, cell cycle analysis, Annexin V assay, and caspase-3/7 activity assay revealed that AT9283 increased the cell population in the G2/M phase and induced apoptosis. We investigated the molecular mechanisms underlying the decrease in cell viability upon treatment with AT9283 by western blotting. Interestingly, our results showed that AT9283 inhibited the expression of Aurora A, Aurora B, and downstream Histone H3 phosphorylation. In contrast, we observed no changes in the levels of Bcr-Abl, signal transducer and activator of transcription 3 (STAT3), extracellular signal-regulated kinase (ERK), and Akt phosphorylation. In addition, we found that AMG900, a selective Aurora A and Aurora B inhibitor, increased the G2/M phase cell population and induced apoptosis via inhibition of Aurora A and Aurora B in both TKI-sensitive and TKI-resistant CML cells. Our studies show that Aurora A and Aurora B are promising therapeutic targets for TKI-sensitive and TKI-resistant CML, and AT9283 may have potential clinical applications for the treatment of TKI-resistant CML patients.

Introduction

Chronic myeloid leukemia (CML), a hematological malignancy, occurs as a result of the presence of the Bcr-Abl fusion protein (1). The Bcr-Abl fusion protein constitutively activates tyrosine kinase activity and induces many downstream signaling pathways, such as phosphoinositide 3 kinase (PI3K)/Akt, Janus kinase (JAK)/signal transducer and activator of transcription (STAT) and mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathways, contributing to cell survival and proliferation (2,3). Imatinib, a tyrosine kinase inhibitor (TKI) that binds to the ATP-binding site of ABL, has dramatically advanced the treatment of CML by inducing long-term overall survival rates of > 90% (4). However, approximately 35% of patients develop pharmacological resistance to imatinib (5). To overcome this resistance, second-generation (dasatinib, nilotinib, and bosutinib) and third-generation (ponatinib) TKIs have been developed and have been shown to be effective against refractory CML patients (6,7). Although these drugs provide many benefits for patients with CML, advanced patients show resistance even to these TKIs (8). Therefore, novel therapeutic strategies are urgently needed for the treatment of TKI-resistant CML patients.

The Aurora family of serine/threonine kinases is essential for many cellular functions, including centrosome function, spindle assembly, chromosome segregation, and cytokinesis (9,10). They comprise Aurora A and Aurora B, and elevated expression of Aurora A and Aurora B have been shown in human cancers such as breast, ovarian, gastric, colon, and pancreatic cancers (11,12). Furthermore, inhibition of Aurora A and Aurora B has proven to be an attractive anticancer approach for a variety of cancers including solid tumors and hematological malignancies (13-15).

Correspondence to: Dr Shozo Nishida, Division of Pharmacotherapy, Kindai University School of Pharmacy, 3-4-1 Kowakae, Higashi-Osaka, Osaka 577-8502, Japan
E-mail: nishida@phar.kindai.ac.jp

Abbreviations: CML, chronic myeloid leukemia; TKI, tyrosine kinase inhibitor; K562/IR, imatinib-resistant K562 cells; JAK, Janus kinase; ERK1/2, extracellular signal-regulated kinase 1/2; STAT3, signal transducer and activator of transcription 3

Key words: chronic myeloid leukemia, AT9283, Aurora A, Aurora B, imatinib
Therefore, inhibiting Aurora kinase is a potential target for the treatment of CML. JAK has long been recognized to be involved in CML pathogenesis (16). JAKs are cytoplasmic protein tyrosine kinases, and dysregulation of the JAK/STAT pathways is critically involved in the survival and proliferation of CML cells (17). Therefore, blocking the JAK/STAT pathway may also represent a novel therapeutic strategy for CML patients.

AT9283 is a multi-targeted kinase inhibitor, discovered using a fragment-based approach, with potent activity against JAK, Aurora kinases, and Abl (18). Previous studies have shown that AT9283 has therapeutic potential in leukemic cells, myeloproliferative disorders, and colon cells (19). In our previous study, the K562/IR cell line (imatinib-resistant CML cells) was established, and K562/IR exhibited resistance to TKIs including imatinib, nilotinib, dasatinib, bafetinib, and ponatinib (20). Here, we showed that AT9283 significantly decreased the cell viability of both TKI-sensitive and TKI-resistant CML cells, including K562/IR. Furthermore, we investigated the molecular mechanisms underlying the decrease in the cell viability. Importantly, we found the critical role of Aurora A and Aurora B in the antiproliferative effects of AT9283 in both TKI-sensitive and TKI-resistant CML cells. Our studies suggest that Aurora A and Aurora B are promising therapeutic targets in TKI-sensitive and TKI-resistant CML, and AT9283 may have potential clinical applications for CML treatment.

Materials and methods

Materials. AT9283 and AMG900 (Adooq Bioscience) were first dissolved in dimethyl sulfoxide (DMSO) to a concentration of 50 mM (stock solution) and stored at -20°C. These reagents were diluted in phosphate-buffered saline (PBS) before use in the experiments described below.

Cells and culture conditions. The human CML cell line K562 was obtained from the Health Science Research Resources Bank (Osaka, Japan). K562/IR cells were obtained from our laboratory. These cells were maintained in RPMI-1640 medium (Sigma-Aldrich; Merck KGaA) with 10% fetal bovine serum (FBS) (Gibco; Thermo Fisher Scientific, Inc.), 2 mM L-glutamine (Wako Pure Chemical Industries, Ltd.), 25 mM HEPES (Wako Pure Chemical Industries, Ltd.), 100 µg/ml penicillin (Gibco; Thermo Fisher Scientific, Inc.), and 100 U/ml streptomycin (Gibco; Thermo Fisher Scientific, Inc.) at 37°C in 5% CO₂.

Trypan blue exclusion assay. CML cells were plated in 96-well plates at a concentration of 2x10⁴ cells/ml. Then, AT9283 (10, 30, 50, and 100 nM) or AMG900 (10, 50, 100, 300, and 500 nM) were added to the well. After 3 days, CML cells were stained with trypan blue and the number of stained cells was counted at a magnification of x100 using an Olympus CK2 inverted microscope (Olympus Optical Co.).

Cell cycle analysis. Assessment of the cell cycle analysis was performed with the Muse™ cell cycle kit (Merck Millipore), according to the manufacturer's protocol. CML cells were treated with 50 nM AT9283 or 300 nM AMG900 for 2 days. Then, Muse™ cell cycle reagent was added and incubated at room temperature for 30 min in the dark. After incubation, the cell cycle analysis was performed using a Muse Cell Analyzer (Merck Millipore).

Annexin V assay. Measurement of cells undergoing apoptosis was performed with the Muse™ Annexin-V and Dead Cell Assay kit (Merck Millipore), according to the manufacturer's protocol. CML cells were treated with 50 nM AT9283 or 300 nM AMG900 for 2 days. Then, Muse™ Annexin V and dead cell reagent were added. After incubation for 20 min at room temperature, apoptotic cells were applied to a Muse Cell Analyzer (Merck Millipore).

Caspase-3/7 activity assay. Measurement of cells undergoing caspase-3/7 activation was performed using the Muse™ Caspase-3/7 kit (Merck Millipore), according to the manufacturer's protocol. CML cells were treated with 50 nM AT9283 or 300 nM AMG900 for 2 days. Then, Muse™ Caspase-3/7 reagent was added and incubated at 37°C for 30 min. After incubation, Muse™ Caspase 3/7-AAD reagent was added and incubated at room temperature for 5 min. The activation of caspase-3/7 was applied to a Muse Cell Analyzer (Merck Millipore).

Western blotting. CML cells were cultured with different concentrations of AT9283 or AMG900 and lysed using lysis buffer as previously described (21). The protein concentration of the lysate was measured using the BCA protein assay kit (Thermo Fisher Scientific, Inc.). The extracts (40 µg) were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene fluoride (PVDF) membranes (GE Healthcare). The membranes were blocked in TBS plus 5% skim milk and incubated overnight at 4°C with each of the following antibodies: Anti-phospho-Abl (cat. no. 2865; dilution 1:1,000), anti-Abl (cat. no. 2862; dilution 1:1,000), anti-phospho-STAT3 (cat. no. 9131; dilution 1:1,000), anti-STAT3 (cat. no. 9132; dilution 1:1,000), anti-phospho-ERK1/2 (cat. no. 4370; dilution 1:2,000), anti-ERK1/2 (cat. no. 9102; dilution 1:2,000), anti-phospho-Akt (cat. no. 9271; dilution 1:1,000), anti-Akt (cat. no. 9272; dilution 1:1,000), anti-phospho-Aurora A (cat. no. 2914; dilution 1:1,000), anti-Aurora A (cat. no. 4718; dilution 1:1,000), anti-phospho-Aurora B (cat. no. 2914; dilution 1:1,000), anti-Aurora B (cat. no. 3094; dilution 1:1,000), anti-phospho-Histone H3 (cat. no. 3377; dilution 1:1,000), anti-Histone H3 (cat. no. 4499; dilution 1:1,000); all from Cell Signaling Technology, Inc.), anti-β-actin (product no. A2228; dilution 1:3,000; Sigma-Aldrich; Merck KGaA), and anti-Lamin A/C (cat. no. sc-20681; dilution 1:1,000; Santa Cruz Biotechnologies, Inc.) secondary antibody.

The proteins were visualized using Luminata Forte Western HRP substrate (Merck Millipore) according to the manufacturer's instructions. The quantities of reactive proteins were determined based on densitometric measurements using a CS analyzer (ATTO, Tokyo, Japan).

Statistical analysis. All results are expressed as the mean ± standard deviation (SD) of three independent experiments. All analyses were conducted using SPSS version 21.0 software (IBM Corp.), and Shapiro-Wilk analysis and one-way analysis of variance (ANOVA) followed by Dunnett's test. P-value <0.05 was considered as indicative of a statistically significant result.
Results

AT9283 decreases the cell viability of TKI-sensitive and TKI-resistant CML cells. We first investigated the effect of AT9283 on the cell viability using the trypan blue assay. We used the human CML cell line K562 and TKI-resistance cell line K562/IR. In our previous study, we showed that K562/IR exhibits resistance to TKIs including imatinib, nilotinib, dasatinib, bafetinib, and ponatinib (20). These cells were treated with AT9283 (10, 30, 50, and 100 nM) for 3 days. We found that AT9283 decreased the cell viability of both K562 (Fig. 1A) and K562/IR (Fig. 1B) cell lines in a concentration-dependent
manner. These results suggest that AT9283 decreases the cell viability of both TKI-sensitive and TKI-resistant CML cells.

AT9283 increases the cell population in the G2/M phase and induces apoptosis of TKI-sensitive and TKI-resistant CML cells. AT9283 has been reported to arrest the G2/M phase in tumor cells, ultimately leading to cell death by apoptosis (18). Therefore, we confirmed the effects of AT9283 on the cell cycle profile and the induction of apoptosis of CML cells (K562 and K562/IR). CML cells were treated with 50 nM AT9283 for 2 days, and the cell cycle profile was determined using the Muse™ cell cycle kit. As expected, AT9283-treated CML cells (K562 and K562/IR) showed an increase in the G2/M phase (Fig. 2A). To further examine whether AT9283 induced apoptosis in CML cells, these cells were treated with 50 nM AT9283 for 2 days, and the number of apoptotic cells was measured using the Muse Annexin V and Dead Cell Assay kit. Our results showed that AT9283 treatment increased the number of total apoptotic cells in both K562 cells and K562/IR cell lines (Fig. 2B). Apoptosis is induced by an interaction between
various initiator and effector caspases (22, 23). Therefore, we confirmed the effects of AT9283 on caspase-3/7 activity in CML cells (K562 and K562/IR). CML cells were treated with 50 nM AT9283 for 2 days, and the caspase-3/7 activity was determined using the Muse™ Caspase -3/7 kit. We showed that AT9283 increased caspase-3/7 activity in both K562 cells and K562/IR cell lines (Fig. 2C). These results indicated that the decreased cell viability upon treatment with AT9283 is attributed to an increase in the G2/M phase and induction of apoptosis.

AT9283 suppresses Histone H3 phosphorylation via inhibition of Aurora A and Aurora B in TKI-sensitive and TKI-resistant CML cells. AT9283 is a multi-targeted kinase inhibitor such as Abl, Aurora kinases, and JAK (18). To clarify the molecular mechanisms underlying the decrease in cell viability upon treatment with AT9283, we investigated the expression of phosphorylated Bcr-Abl, Aurora A, Aurora B, downstream STAT3, ERK, Akt, and Histone H3 in CML cells with AT9283 (10, 30, and 50 nM) by western blotting. Interestingly, our results showed that AT9283 significantly decreased the expression of Aurora A, Aurora B, and Histone H3 phosphorylation in both K562 cells and K562/IR cell lines, whereas we observed no changes in the levels of Bcr-Abl, STAT3, ERK, and Akt phosphorylation (Fig. 3). These results suggest that the decreased cell viability upon treatment with AT9283 may be involved in the inhibition of Histone H3 by decreasing the expression of phosphorylated Aurora A and Aurora B in both TKI-sensitive and TKI-resistant CML cells.

AMG900 increases G2/M phase and induces apoptosis via inhibition of Aurora A and Aurora B of TKI-sensitive and
AT9283 has antiproliferative effect on TKI-sensitive and -resistant CML cells. We further examined the role of Aurora A and Aurora B in the anticancer activity of AT9283 by using a selective AuroraA/B inhibitor AMG900. We showed that AMG900 decreased the cell viability and the expression of Aurora A, Aurora B, and Histone H3 phosphorylation in both K562 cells and K562/IR cell lines (Fig. 4). We also observed that AMG900 increased the G2/M phase population and significantly induced apoptosis and caspase 3/7 activity (Fig. 5). These results support the critical role of Aurora A and Aurora B in the antiproliferative effects of AT9283 in both TKI-sensitive and TKI-resistant CML cells.

**Discussion**

In the present study, we investigated the effects of AT9283, a multi-targeted kinase inhibitor, in tyrosine kinase inhibitor (TKI)-sensitive chronic myeloid leukemia (CML) cells (K562) and TKI-resistant CML cells (K562/IR). We showed that AT9283 decreased the cell viability of both TKI-sensitive and TKI-resistant CML cells. In addition, we found that AT9283 increased the G2/M phase population and cell death by apoptosis. Preclinical studies have shown that AT9283 has potent cytotoxic and cell growth inhibitory activity in vitro as well as antitumor activity in vivo in a mouse xenograft model of colon carcinoma (18,19). Furthermore, AT9283 has been reported to increase the G2/M phase and induce apoptosis of multiple myeloma and B-cell lymphoma cells in a time-dependent manner (19,24). These results suggest that AT9283 may have potential clinical applications for the treatment of TKI-sensitive and TKI-resistant CML patients.

Differential sensitivity of AT9283 between K562 and K562/IR was observed. In our previous study, we showed that activation of MET in K562/IR cells was increased compared to K562 cells (20). MET is an oncogene encoding tyrosine kinase receptor, and plays an important role in embryogenesis, tumor growth, and metastasis (25). In addition, MET activation was reported to be associated with poorer response to chemotherapy. Therefore, differential sensitivity of AT9283 between K562 and K562/IR cell lines may involve MET activation. Further research will be carried out to investigate the differential sensitivity of AT9283 between K562 and K562/IR cells in the future.

AT9283 is a multi-targeted kinase inhibitor against Abl, Aurora kinases, and JAK (18). However, the molecular mechanisms underlying the decrease in cell viability of TKI-sensitive and TKI-resistant CML cells upon treatment with AT9283 was not unclear. Interestingly, our results showed that AT9283 decreased the expression of Aurora A, Aurora B, and Histone H3 phosphorylation. In contrast, we observed no changes in the levels of Bcr-Abl, STAT3, ERK, and Akt phosphorylation. Furthermore, we showed that AMG900, a selective Aurora A and Aurora B inhibitor, increased the G2/M phase cell population and induced apoptosis via the inhibition of Aurora A and Aurora B of both TKI-sensitive and TKI-resistant CML
cells. Aurora A localizes to centrosomes during the G2 phase and is required for the separation and maturation of centrosomes through the recruitment of key components of spindle assembly (26). Aurora B kinase is also a chromosomal passenger protein that is essential for chromosome segregation through the phosphorylation of mitotic histone H3 (27,28). Recent studies have reported that a decrease in Aurora A or Aurora B leads to G2/M arrest, spindle defects, and multi-nucleated cells, which eventually undergo apoptosis (29,30). In addition, Aurora B kinase RNAi was evidenced by the inhibition of Histone H3 phosphorylation and endoreduplication, which leads to apoptosis in colon cancer cells (31). These results support the critical role of Aurora A and Aurora B in the antiproliferative effects of AT9283 in TKI-sensitive and TKI-resistant CML cells.

Differential cell viability between AT9283 and AMG900 in K562 and K562/IR was observed. In previous studies, AT9283 inhibited Aurora kinase at low concentration compared with AMG900 (18,32). Furthermore, our results showed that 30-50 nM of AT9283 inhibited the expression of Aurora A and Aurora B phosphorylation, whereas 100-300 nM of AMG900 inhibited the expression of Aurora A and Aurora B phosphorylation. Therefore, AT9283 may inhibit Aurora A and Aurora B more strongly than AMG900.

Different markers have been reported to predict the efficacy of Aurora inhibitors such as DNA aneuploidy, mitotic index, and percentage of aligned spindles in G2/M phase (33,34). In normal cells, Aurora A and Aurora B are expressed in a cell cycle-dependent manner, peaking during the G2/M phase (35). Several transcription factors, such as E2F-1, E2F-4, DP-2 and FoxM1 have been reported to be implicated in cell cycle-regulated transcription of Aurora A and Aurora B (36-38). However, limited information is available concerning regulation of Aurora A and Aurora B expression in malignant tumors. Therefore, identifying the regulator of Aurora A and Aurora B will be an important task to clarify possible biomarkers of AT9283 in CML treatment.

Although the development of imatinib has led to an extended lifespan for many CML patients, the development of imatinib resistance represents a relevant clinical issue in the treatment of CML (39). To overcome this resistance, second-generation TKIs (nilotinib, dasatinib, and bosutinib) have been developed and are effective against a range of Bcr-Abl mutations (e.g., E255K, M351T), except for T315I (40,41). In addition, third-generation TKI ponatinib has activity against Bcr-Abl mutations, including T315I (42).

Although these drugs provide many benefits for patients with CML, in 50% of imatinib-resistant CML patients, there is no mutation in Bcr-Abl. Furthermore, the treatment of CML patients with Bcr-Abl-independent imatinib resistance has been disappointing. In the present study, we used K562/IR cells which did not have any Bcr-Abl mutations (20). Interestingly, our results showed that AT9283 decreased the cell viability of K562/IR cells in a concentration-dependent manner. Furthermore, AT9283 inhibited the expression of Aurora A, Aurora B, and downstream Histone H3 phosphorylation in K562/IR cells. Thus, our research provides new insights that Aurora A and Aurora B are promising therapeutic targets in Bcr-Abl-independent imatinib resistance, and AT9283 may have potential clinical application for the treatment of TKI-resistant CML patients with Bcr-Abl-independent imatinib resistance.

In conclusion, AT9283 decreased the cell viability of both TKI-sensitive and TKI-resistant CML cells. The decrease in cell viability was attributed to an increase in the G2/M phase population and induction of apoptosis via inhibition of Aurora A and Aurora B. Our research suggests that Aurora A and Aurora B are promising therapeutic targets in TKI-sensitive and TKI-resistant CML, and AT9283 may have potential clinical applications for CML treatment.

Acknowledgements

Not applicable.

Funding

This study was supported in part by a Grant-in-Aid for Young Scientists from the Japan Society for the Promotion of Science (JSPS).

Availability of data and materials

The datasets used during the present study are available from the corresponding author upon reasonable request.

Authors' contributions

TT performed the analysis of the trypan blue exclusion assay, cell cycle analysis, and western blotting and drafted the manuscript. MT, SG, CN and YO carried out analysis of the trypan blue exclusion assay, Annexin V assay, caspase-3/7 activity assay, and western blotting. M1 and TS contributed to the statistical analyses. SN designed the experiments and revised the manuscript. All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


